×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Skip to main content
Tags: sickle cell disease | fda | gene-editing | casgevy | vertex | crispr therapeutics | lyfgenia

FDA Approves Two Sickle Cell Disease Gene Therapies

red blood cells under microscope of a patient with sickle cell disease
(Dreamstime)

Friday, 08 December 2023 11:35 AM EST

The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

The agency approved Lyfgenia from bluebird bio, and a separate treatment called Casgevy by partners Vertex Pharmaceuticals and CRISPR Therapeutics.

Both the therapies were approved for people aged 12 years and older.

The Vertex/CRISPR gene therapy uses the breakthrough gene editing technology that won its inventors the Nobel Prize in 2020.

Sickle cell disease is a painful, inherited blood disorder that can be debilitating and lead to premature death. It affects an estimated 100,000 people in the United States, most of whom are Black.

In sickle cell disease, the body makes flawed, sickle-shaped hemoglobin, impairing the ability of red blood cells to properly carry oxygen to the body's tissues.

The sickle cells tend to stick together and can block small blood vessels, causing intense pain. It also can lead to strokes and organ failure.

U.S.-listed shares of CRISPR therapeutics were up 1.6%, while Vertex Pharmaceuticals stock was down 1.4%. Shares of bluebird bio were halted for trading ahead of the news.

Makers of both the therapies have pitched them as one-time treatments, but data on how long their effect lasts is limited. The only longer-term treatment for sickle cell disease is a bone marrow transplant.

"I actually am very reticent to call them a cure. I prefer to call them a transformative therapy because patients will still have sickle cell disease on the other side of gene therapy," said Dr Sharl Azar, medical director of the Comprehensive Sickle Cell Disease Treatment Center at Massachusetts General Hospital.

Bluebird bio's sickle cell therapy is designed to work by inserting modified genes into the body through disabled viruses to help the patient's red blood cells produce normal hemoglobin.

For Vertex's therapy, patients must have stem cells harvested from their bone marrow. The cells are then sent to manufacturing facilities where they are edited using CRISPR/Cas9 technology. Once the cells are incubated, they are infused back into the patient during a month-long hospital stay.

Both gene therapies can take several months and involve high-dose chemotherapy, but this has potential risks of infertility.

"Not everybody who undergoes chemotherapy will end up having infertility, but the majority of them will," said Dr Azar.

While the risk can be managed by fertility preservation methods like freezing eggs and sperm banking, this is only covered by insurance for cancer patients who undergo chemotherapy and not those receiving gene therapy, said Dr. Azar.

He said the out-of-pocket expense on it can be as high as $40,000.

FDA staff in documents released ahead of an October meeting of a panel of independent experts on Vertex's therapy had also flagged concerns of unintended genomic alterations from the treatment.

The company plans to assess potential long-term safety risks through a 15-year follow-up study after approval.

Vertex's CRISPR therapy is also under an FDA review for another blood disease, transfusion-dependent beta thalassemia, with a decision expected by March 30.

© 2024 Thomson/Reuters. All rights reserved.


Health-News
The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.The agency approved Lyfgenia from bluebird bio, and a separate treatment...
sickle cell disease, fda, gene-editing, casgevy, vertex, crispr therapeutics, lyfgenia, bluebird bio
507
2023-35-08
Friday, 08 December 2023 11:35 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Interest-Based Advertising | Do not sell or share my personal information

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
Get the NewsmaxTV App for iOS Get the NewsmaxTV App for Android Scan QR code to get the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved